Investigational Drug Details
| Drug ID: | D602 |
| Drug Name: | IGF-I |
| Synonyms: | -- |
| Type: | Miscellany |
| DrugBank ID: | -- |
| DrugBank Description: | -- |
| PubChem ID: | -- |
| CasNo: | -- |
| Repositioning for NAFLD: | No |
| SMILES: | -- |
| InChiKey: | -- |
| Molecular Weight: | -- |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | P53 activitor |
| Therapeutic Category: | Anti-fibrosis |
| Clinical Trial Progress: | -- |
| Latest Progress: | Under investigation |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A01925 | 34560554 | Biomed Pharmacother | Regulation of decorin by ursolic acid protects against non-alcoholic steatohepatitis. | Details |
| A03110 | 34126247 | Endocr Pract | High Prevalence of Nonalcoholic Fatty Liver Disease Among Adolescents and Young Adults With Hypopituitarism due to Growth Hormone Deficiency. | Details |
| A14476 | 29395967 | Growth Horm IGF Res | Factors correlated with serum insulin-like growth factor-I levels in health check-up subjects. | Details |
| A15404 | 28927302 | Scand J Gastroenterol | IGFBP-1 and IGF-I as markers for advanced fibrosis in NAFLD - a pilot study. | Details |
| A15859 | 28678199 | Int J Mol Sci | The Role of Growth Hormone and Insulin-Like Growth Factor-I in the Liver. | Details |
| A17606 | 27721459 | Sci Rep | IGF-I induces senescence of hepatic stellate cells and limits fibrosis in a p53-dependent manner. | Details |
| A17786 | 27594563 | Postepy Hig Med Dosw (Online) | New peptides players in metabolic disorders. | Details |
| A21549 | 25238938 | Pathol Res Pract | Histopathological aspects of liver under variable food restriction: has the intense one-week food restriction a protective effect on non-alcoholic-fatty-liver-disease (NAFLD) development? | Details |
| A22161 | 30736156 | Expert Rev Endocrinol Metab | Insulin-like growth factors (IGF-I and -II): new actors in the development of non-alcoholic fatty liver disease. | Details |
| A22408 | 24607243 | J Pediatr | Insulin-like growth factor-I and -II levels are associated with the progression of nonalcoholic fatty liver disease in obese children. | Details |
| A23998 | 23316084 | J Clin Endocrinol Metab | Insulin-like growth factor-I, inflammatory proteins, and fibrosis in subjects with nonalcoholic fatty liver disease. | Details |
| A24339 | 22986486 | Endocr J | Essential roles of growth hormone (GH) and insulin-like growth factor-I (IGF-I) in the liver. | Details |
| A24641 | 22659415 | Biochem Biophys Res Commun | GH-independent IGF-I action is essential to prevent the development of nonalcoholic steatohepatitis in a GH-deficient rat model. | Details |
| A25227 | 22077984 | Clin Endocrinol (Oxf) | Nonalcoholic fatty liver disease is associated with increased GHBP and reduced GH/IGF-I levels. | Details |
| A25234 | 22067322 | Endocrinology | Prenatal dexamethasone exposure potentiates diet-induced hepatosteatosis and decreases plasma IGF-I in a sex-specific fashion. | Details |
| A25454 | 21816784 | J Clin Endocrinol Metab | Nonalcoholic fatty liver disease is associated with low circulating levels of insulin-like growth factor-I. | Details |
| A27402 | 18462969 | Growth Horm IGF Res | Nonalcoholic fatty liver in patients with Laron syndrome and GH gene deletion - preliminary report. | Details |
| A34223 | 24045151 | J Hepatol | A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma. | Details |
| A35433 | 20693650 | J Alzheimers Dis | Ceramide-mediated insulin resistance and impairment of cognitive-motor functions. | Details |
| A45248 | 27508202 | J Hepatocell Carcinoma | Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma. | Details |